These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 32528733)

  • 1. Single-administration, thermostable human papillomavirus vaccines prepared with atomic layer deposition technology.
    Garcea RL; Meinerz NM; Dong M; Funke H; Ghazvini S; Randolph TW
    NPJ Vaccines; 2020; 5(1):45. PubMed ID: 32528733
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Single Dose, Thermostable, Trivalent Human Papillomavirus Vaccine Formulated Using Atomic Layer Deposition.
    Witeof AE; Meinerz NM; Walker KD; Funke HH; Garcea RL; Randolph TW
    J Pharm Sci; 2023 Aug; 112(8):2223-2229. PubMed ID: 36780987
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Atomic-Layer Deposition Processes Applied to Phage λ and a Phage-like Particle Platform Yield Thermostable, Single-Shot Vaccines.
    Witeof AE; McClary WD; Rea LT; Yang Q; Davis MM; Funke HH; Catalano CE; Randolph TW
    J Pharm Sci; 2022 May; 111(5):1354-1362. PubMed ID: 35081408
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of a highly thermostable, adjuvanted human papillomavirus vaccine.
    Hassett KJ; Meinerz NM; Semmelmann F; Cousins MC; Garcea RL; Randolph TW
    Eur J Pharm Biopharm; 2015 Aug; 94():220-8. PubMed ID: 25998700
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thermostability of a trivalent, capsomere-based vaccine for human papillomavirus infection.
    Dong M; Meinerz NM; Walker KD; Garcea RL; Randolph TW
    Eur J Pharm Biopharm; 2021 Nov; 168():131-138. PubMed ID: 34438020
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Induction of protective immunity against H1N1 influenza A(H1N1)pdm09 with spray-dried and electron-beam sterilised vaccines in non-human primates.
    Scherließ R; Ajmera A; Dennis M; Carroll MW; Altrichter J; Silman NJ; Scholz M; Kemter K; Marriott AC
    Vaccine; 2014 Apr; 32(19):2231-40. PubMed ID: 24631078
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine.
    Harro CD; Pang YY; Roden RB; Hildesheim A; Wang Z; Reynolds MJ; Mast TC; Robinson R; Murphy BR; Karron RA; Dillner J; Schiller JT; Lowy DR
    J Natl Cancer Inst; 2001 Feb; 93(4):284-92. PubMed ID: 11181775
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preclinical refinements of a broadly protective VLP-based HPV vaccine targeting the minor capsid protein, L2.
    Tumban E; Muttil P; Escobar CA; Peabody J; Wafula D; Peabody DS; Chackerian B
    Vaccine; 2015 Jun; 33(29):3346-53. PubMed ID: 26003490
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of the thermal stability and the protective efficacy of spray-dried HPV vaccine, Gardasil® 9.
    Kunda NK; Peabody J; Zhai L; Price DN; Chackerian B; Tumban E; Muttil P
    Hum Vaccin Immunother; 2019; 15(7-8):1995-2002. PubMed ID: 30883270
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Minor Capsid Protein L2 Polytope Induces Broad Protection against Oncogenic and Mucosal Human Papillomaviruses.
    Pouyanfard S; Spagnoli G; Bulli L; Balz K; Yang F; Odenwald C; Seitz H; Mariz FC; Bolchi A; Ottonello S; Müller M
    J Virol; 2018 Feb; 92(4):. PubMed ID: 29212932
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Heterologous DNA-prime/protein-boost immunization with a monomeric SARS-CoV-2 spike antigen redundantizes the trimeric receptor-binding domain structure to induce neutralizing antibodies in old mice.
    Pflumm D; Seidel A; Klein F; Groß R; Krutzke L; Kochanek S; Kroschel J; Münch J; Stifter K; Schirmbeck R
    Front Immunol; 2023; 14():1231274. PubMed ID: 37753087
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reconstituted dry powder formulations of ZnO-adjuvanted ovalbumin induce equivalent antigen specific antibodies but lower T cell responses than ovalbumin adjuvanted with Alhydrogel® or cationic adjuvant formulation 01 (CAF®01).
    Hellfritzsch M; Christensen D; Foged C; Scherließ R; Thakur A
    Int J Pharm; 2023 Dec; 648():123581. PubMed ID: 37931728
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vaccination with human papillomavirus pseudovirus-encapsidated plasmids targeted to skin using microneedles.
    Kines RC; Zarnitsyn V; Johnson TR; Pang YY; Corbett KS; Nicewonger JD; Gangopadhyay A; Chen M; Liu J; Prausnitz MR; Schiller JT; Graham BS
    PLoS One; 2015; 10(3):e0120797. PubMed ID: 25785935
    [TBL] [Abstract][Full Text] [Related]  

  • 14. IgG and IgM responses to human papillomavirus L1 virus-like particle as a function of dosing schedule and vaccine formulation.
    Park MH; You JW; Kim HJ; Kim HJ
    J Microbiol; 2019 Sep; 57(9):821-827. PubMed ID: 31452045
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Demonstration of Tunable Control over a Delayed-Release Vaccine Using Atomic Layer Deposition.
    Brubaker SW; Walters IR; Hite EM; Antunez LR; Palm EL; Funke HH; Steadman BL
    Vaccines (Basel); 2024 Jul; 12(7):. PubMed ID: 39066399
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of varying antigens and adjuvant systems on the immunogenicity and safety of investigational tetravalent human oncogenic papillomavirus vaccines: results from two randomized trials.
    Van Damme P; Leroux-Roels G; Simon P; Foidart JM; Donders G; Hoppenbrouwers K; Levin M; Tibaldi F; Poncelet S; Moris P; Dessy F; Giannini SL; Descamps D; Dubin G
    Vaccine; 2014 Jun; 32(29):3694-705. PubMed ID: 24674663
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lyophilized Filovirus Glycoprotein Vaccines: Peroxides in a Vaccine Formulation with Polysorbate 80-Containing Adjuvant are Associated with Reduced Neutralizing Antibody Titers in Both Mice and Non-Human Primates.
    Preston KB; Wong TAS; Lieberman MM; To A; Lai CY; Granados A; Thomasson H; Misamore J; Yalley-Ogunro J; Cabus M; Andersen H; Donini O; Lehrer AT; Randolph TW
    J Pharm Sci; 2022 Dec; 111(12):3424-3434. PubMed ID: 35609629
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A respirable HPV-L2 dry-powder vaccine with GLA as amphiphilic lubricant and immune-adjuvant.
    Rossi I; Spagnoli G; Buttini F; Sonvico F; Stellari F; Cavazzini D; Chen Q; Müller M; Bolchi A; Ottonello S; Bettini R
    J Control Release; 2021 Dec; 340():209-220. PubMed ID: 34740725
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Spray-Dried Influenza Antigen with Trehalose and Leucine Produces an Aerosolizable Powder Vaccine Formulation that Induces Strong Systemic and Mucosal Immunity after Pulmonary Administration.
    Sou T; Morton DA; Williamson M; Meeusen EN; Kaminskas LM; McIntosh MP
    J Aerosol Med Pulm Drug Deliv; 2015 Oct; 28(5):361-71. PubMed ID: 25714115
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimized Formulation of a Thermostable Spray-Dried Virus-Like Particle Vaccine against Human Papillomavirus.
    Saboo S; Tumban E; Peabody J; Wafula D; Peabody DS; Chackerian B; Muttil P
    Mol Pharm; 2016 May; 13(5):1646-55. PubMed ID: 27019231
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.